On June 10, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech firm focusing on advanced oral treatments for neurologic disorders, disclosed its involvement in various investor, industry, and scientific conferences happening this month. The company's participation in these events highlights its commitment to advancing medical innovation and sharing insights within the field. This aligns with Immunic's mission to address the unmet medical needs of patients. Through these engagements, Immunic aims to showcase its potential in transforming the treatment landscape for neurologic diseases.